GNI Group, controlling shareholder of Gyre Therapeutics, raises FY2023 forecast; revenue +3.9%, op profit +21.5%

GYRE THERAPEUTICS, INC.

2023-Q3 EPS reported -$0.10 revenue$86,302,000

FY2023 revenue forecast raised to ¥26,267M (from ¥25,273M); operating profit to ¥7,280M (from ¥5,991M).
Net profit attributable to parent raised to ¥2,005M; basic EPS revised to ¥42.20 from ¥35.86.
ETUARY® sales in China exceeded expectations; Cullgen's Astellas alliance revenue above prior forecast.
Forex assumptions revised: US$1=¥138.24 and RMB1=¥19.62 (from ¥130.77 and ¥19.38).
Previous 2022 actuals: revenue ¥17,418M, net profit ¥388M, EPS ¥8.19.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.